MEDP Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of 18.08% compared to Medpace Holdings's net margin of --. Medpace Holdings's return on equity of 54.64% beat CEL-SCI's return on equity of --.

Medpace Holdings has a consensus price target of $347.92, signalling upside risk potential of 3.07%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 959.51%. Given that CEL-SCI has higher upside potential than Medpace Holdings, analysts believe CEL-SCI is more attractive than Medpace Holdings.

Medpace Holdings has a beta of 1.367, which suggesting that the stock is 36.674% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Medpace Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medpace Holdings pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Medpace Holdings quarterly revenues are $533.3M, which are larger than CEL-SCI quarterly revenues of --. Medpace Holdings's net income of $96.4M is higher than CEL-SCI's net income of -$6.9M. Notably, Medpace Holdings's price-to-earnings ratio is 29.56x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medpace Holdings is 5.22x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Fortrea Holdings has a net margin of 18.08% compared to Medpace Holdings's net margin of -4.13%. Medpace Holdings's return on equity of 54.64% beat Fortrea Holdings's return on equity of -18.75%.

Medpace Holdings has a consensus price target of $347.92, signalling upside risk potential of 3.07%. On the other hand Fortrea Holdings has an analysts' consensus of $23.29 which suggests that it could grow by 20.93%. Given that Fortrea Holdings has higher upside potential than Medpace Holdings, analysts believe Fortrea Holdings is more attractive than Medpace Holdings.

Medpace Holdings has a beta of 1.367, which suggesting that the stock is 36.674% more volatile than S&P 500. In comparison Fortrea Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medpace Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortrea Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medpace Holdings pays -- of its earnings as a dividend. Fortrea Holdings pays out -- of its earnings as a dividend.

Medpace Holdings quarterly revenues are $533.3M, which are smaller than Fortrea Holdings quarterly revenues of $674.9M. Medpace Holdings's net income of $96.4M is higher than Fortrea Holdings's net income of -$27.9M. Notably, Medpace Holdings's price-to-earnings ratio is 29.56x while Fortrea Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medpace Holdings is 5.22x versus 0.58x for Fortrea Holdings. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of 18.08% compared to Medpace Holdings's net margin of -416.75%. Medpace Holdings's return on equity of 54.64% beat IGC Pharma's return on equity of -137.43%.

Medpace Holdings has a consensus price target of $347.92, signalling upside risk potential of 3.07%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 889.45%. Given that IGC Pharma has higher upside potential than Medpace Holdings, analysts believe IGC Pharma is more attractive than Medpace Holdings.

Medpace Holdings has a beta of 1.367, which suggesting that the stock is 36.674% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Medpace Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medpace Holdings pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Medpace Holdings quarterly revenues are $533.3M, which are larger than IGC Pharma quarterly revenues of $412K. Medpace Holdings's net income of $96.4M is higher than IGC Pharma's net income of -$1.7M. Notably, Medpace Holdings's price-to-earnings ratio is 29.56x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medpace Holdings is 5.22x versus 22.17x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings has a net margin of 18.08% compared to Medpace Holdings's net margin of 7.32%. Medpace Holdings's return on equity of 54.64% beat IQVIA Holdings's return on equity of 21.99%.

Medpace Holdings has a consensus price target of $347.92, signalling upside risk potential of 3.07%. On the other hand IQVIA Holdings has an analysts' consensus of $249.54 which suggests that it could grow by 26.5%. Given that IQVIA Holdings has higher upside potential than Medpace Holdings, analysts believe IQVIA Holdings is more attractive than Medpace Holdings.

Medpace Holdings has a beta of 1.367, which suggesting that the stock is 36.674% more volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.486, suggesting its more volatile than the S&P 500 by 48.559%.

Medpace Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medpace Holdings pays -- of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend.

Medpace Holdings quarterly revenues are $533.3M, which are smaller than IQVIA Holdings quarterly revenues of $3.9B. Medpace Holdings's net income of $96.4M is lower than IQVIA Holdings's net income of $285M. Notably, Medpace Holdings's price-to-earnings ratio is 29.56x while IQVIA Holdings's PE ratio is 25.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medpace Holdings is 5.22x versus 2.37x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.